Abstract:Aims/hypothesis: Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. A growing number of T cell-directed therapeutics have demonstrated partial therapeutic efficacy, with anti-CD3 (α-CD3) representing the only regulatory agency-approved drug capable of slowing disease progression through a mechanism involving the induction of partial T cell exhaustion. There is an outstanding need to augment the durability and effectiveness of T cell targeting by directly restraining proinflammatory T helper type 1 (Th1) and type 1 cytotoxic CD8+ T cell (Tc1) subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a novel strategy for reducing diabetes incidence in the NOD mouse model using a blocking monoclonal antibody targeting the type 1 diabetes-risk associated T cell co-stimulatory receptor, CD226. Methods: Female NOD mice were treated with anti-CD226 between 7-8 weeks of age and then monitored for diabetes incidence and therapeutic mechanism of action. Results: Compared to isotype-treated controls, anti-CD226 treated NOD mice showed reduced insulitis severity at 12 weeks and decreased disease incidence at 30 weeks. Flow cytometric analysis performed five weeks post-treatment demonstrated reduced proliferation of CD4+ and CD8+ effector memory T cells in spleens of anti-CD226 treated mice. Phenotyping of pancreatic Tregs revealed increased CD25 expression and STAT5 phosphorylation following anti-CD226, with splenic Tregs displaying augmented suppression of CD4+ T cell responders in vitro. Anti-CD226 treated mice exhibited reduced frequencies of islet-specific glucose-6-phosphatase catalytic subunit related protein (IGRP)-reactive CD8+ T cells in the pancreas, using both ex vivo tetramer staining and single-cell T cell receptor sequencing (scTCR-seq) approaches. 51Cr-release assays demonstrated reduced cell-mediated lysis of beta-cells by anti-CD226-treated autoreactive cytotoxic T lymphocytes. Conclusions/interpretation: CD226 blockade reduces T cell cytotoxicity and improves Treg function, representing a targeted and rational approach for restoring immune regulation in type 1 diabetes.

Prevention of Diabetes in NOD Mice by Administration of Dendritic Cells Deficient in Nuclear Transcription Factor-κB Activity

Prevention of Diabetes in NOD Mice by Administration of Dendritic Cells Deficient in Nuclear Transcription Factor-Kappab Activity.

Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer

Insulin-Attenuated Inflammatory Response of Dendritic Cells in Diabetes by Regulating RAGE-PKCβ1-IRS1-NF-κB Signal Pathway: A Study on the Anti-Inflammatory Mechanism of Insulin in Diabetes

The Role of Liver‐derived Regulatory Dendritic Cells in Prevention of Type 1 Diabetes

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Beyond Knockout: A Novel Homodimerization-Targeting MyD88 Inhibitor Prevents and Cures Type 1 Diabetes in NOD Mice

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in Prevention of Autoimmune Diabetes in Non-Obese Diabetic Mice Treated with Alpha-Galactosylceramide.

Effect of NF-kB activity inhibition on function of dendritic cells in human peripheral blood and clinical efficacy of type Ⅰ diabetes

Oral Administration of PDX1 Confers Protection Against Insulitis in the Non-Obese Diabetic (NOD) Mice.

Protective Response Against Type 1 Diabetes in Nonobese Diabetic Mice after Coimmunization with Insulin and Dna Encoding Proinsulin

Regulatory CD4+ T cells redirected against pathogenic CD8+ T cells protect NOD mice from development of autoimmune diabetes

Interleukin‐17‐producing Γδ+ T Cells Protect NOD Mice from Type 1 Diabetes Through a Mechanism Involving Transforming Growth Factor‐β

Inhibition of CD226 Co-Stimulation Suppresses Diabetes Development in the NOD Mouse by Augmenting Tregs and Diminishing Effector T Cell Function

T Regulatory Cells to Prevent Autoimmune Diabetes and Promote Islet Allograft Survival in NOD Mice

GAD-IgG-inducing CD4+Foxp3+Treg Cells Suppressing Diabetes Are Involved in the Increasing Ratio of CD80+:CD86+ Cells in NOD Mice

Enhanced early expansion and maturation of semi-invariant NK T cells inhibited autoimmune pathogenesis in congenic nonobese diabetic mice.

NK3-Like NK Cells Are Involved in Protective Effect of Polyinosinic-Polycytidylic Acid on Type 1 Diabetes in Nonobese Diabetic Mice

The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice

B Lymphocytes Expressing High Levels of PD-L1 Are Key Regulators of Diabetes Development in Non-Obese Diabetic Mice.